Though HPAP shares features with other tumor types, the relatively circumscribed nature of the tumor along with specific molecular clues, particularly loss of chromosome 13 and mutations in RB1 and TP53, should prompt one to consider this entity, especially given its propensity to harbor a better clinical prognosis when compared with other high grade glial neoplasms. This evidence concerns the gene RB1 and neoplasm.